These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 3085844)

  • 1. Analysis of factors associated with the prognosis of cirrhotic patients who were treated with tolvaptan for hepatic edema.
    Atsukawa M; Tsubota A; Takaguchi K; Toyoda H; Iwasa M; Ikegami T; Chuma M; Nozaki A; Uojima H; Hiraoka A; Fukunishi S; Yokohama K; Tada T; Kato K; Abe H; Tani J; Okubo H; Watanabe T; Hattori N; Tsutsui A; Senoh T; Yoshida Y; Okubo T; Itokawa N; Nakagawa-Iwashita A; Kondo C; Arai T; Michitaka K; Iio E; Kumada T; Tanaka Y; Takei Y; Iwakiri K
    J Gastroenterol Hepatol; 2020 Jul; 35(7):1229-1237. PubMed ID: 31881554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
    Villanueva C; Albillos A; Genescà J; Garcia-Pagan JC; Calleja JL; Aracil C; Bañares R; Morillas RM; Poca M; Peñas B; Augustin S; Abraldes JG; Alvarado E; Torres F; Bosch J
    Lancet; 2019 Apr; 393(10181):1597-1608. PubMed ID: 30910320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal Management of Cirrhotic Ascites: A Review for Internal Medicine Physicians.
    Gallo A; Dedionigi C; Civitelli C; Panzeri A; Corradi C; Squizzato A
    J Transl Int Med; 2020 Dec; 8(4):220-236. PubMed ID: 33511049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, open-label, blinded-endpoint, crossover, single-dose study to compare the pharmacodynamics of torasemide-PR 10 mg, torasemide-IR 10 mg, and furosemide-IR 40 mg, in patients with chronic heart failure.
    Ballester MR; Roig E; Gich I; Puntes M; Delgadillo J; Santos B; Antonijoan RM
    Drug Des Devel Ther; 2015; 9():4291-302. PubMed ID: 26273191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cirrhosis and its complications: evidence based treatment.
    Nusrat S; Khan MS; Fazili J; Madhoun MF
    World J Gastroenterol; 2014 May; 20(18):5442-60. PubMed ID: 24833875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sympatho-renal axis in chronic disease.
    Sobotka PA; Mahfoud F; Schlaich MP; Hoppe UC; Böhm M; Krum H
    Clin Res Cardiol; 2011 Dec; 100(12):1049-57. PubMed ID: 21688196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathogenetic background for treatment of ascites and hepatorenal syndrome.
    Møller S; Henriksen JH; Bendtsen F
    Hepatol Int; 2008 Dec; 2(4):416-28. PubMed ID: 19669317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guidelines on the management of ascites in cirrhosis.
    Moore KP; Aithal GP
    Gut; 2006 Oct; 55 Suppl 6(Suppl 6):vi1-12. PubMed ID: 16966752
    [No Abstract]   [Full Text] [Related]  

  • 9. Cardiopulmonary complications in chronic liver disease.
    Moller S; Henriksen JH
    World J Gastroenterol; 2006 Jan; 12(4):526-38. PubMed ID: 16489664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal tubular events following passage from the supine to the standing position in patients with compensated liver cirrhosis: loss of tubuloglomerular feedback.
    Sansoè G; Biava AM; Silvano S; Ferrari A; Rosina F; Smedile A; Touscoz A; Bonardi L; Rizzetto M
    Gut; 2002 Nov; 51(5):736-41. PubMed ID: 12377816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diuretic combinations in refractory oedema states: pharmacokinetic-pharmacodynamic relationships.
    Sica DA; Gehr TW
    Clin Pharmacokinet; 1996 Mar; 30(3):229-49. PubMed ID: 8882303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Which diuretic to use?
    Swanepoel CR
    Cardiovasc Drugs Ther; 1994 Feb; 8(1):123-8. PubMed ID: 8086322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loop diuretics versus others in the treatment of congestive heart failure after myocardial infarction.
    Reyes AJ
    Cardiovasc Drugs Ther; 1993 Dec; 7(6):869-76. PubMed ID: 8011561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined use of water immersion and frusemide in treatment of resistant ascites in liver cirrhosis.
    Fawthrop F; O'Hare JP; Millar N; Weston CF; Read AE
    J R Soc Med; 1987 Dec; 80(12):776-7. PubMed ID: 3430532
    [No Abstract]   [Full Text] [Related]  

  • 15. The influence of posture on the response to loop diuretics in patients with chronic cardiac failure is reduced by angiotensin converting enzyme inhibition.
    Flapan AD; Davies E; Waugh C; Williams BC; Shaw TR; Edwards CR
    Eur J Clin Pharmacol; 1992; 42(6):581-5. PubMed ID: 1623897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacotherapy of ascites associated with cirrhosis.
    Ginès P; Arrovo V; Rodés J
    Drugs; 1992 Mar; 43(3):316-32. PubMed ID: 1374317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diuretic treatment in decompensated cirrhosis and congestive heart failure: effect of posture.
    Ring-Larsen H; Henriksen JH; Wilken C; Clausen J; Pals H; Christensen NJ
    Br Med J (Clin Res Ed); 1986 May; 292(6532):1351-3. PubMed ID: 3085844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of posture on the diuretic treatment of decompensated cirrhosis and heart failure].
    Wilken-Jensen C; Ring-Larsen H; Henriksen JH; Clausen J; Pals H; Christensen NJ
    Ugeskr Laeger; 1989 Jan; 151(1):13-5. PubMed ID: 2911877
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.